9.3 Generic Substitution & Interchangeable Biologics (§6816-a)

Why § 6816-a Uses "Shall," Not "May"

Unlike states where generic substitution is purely discretionary, New York's substitution statute is captioned "When Substitution Is Required" — Education Law § 6816-a uses mandatory language: a pharmacist "shall substitute" a less expensive, therapeutically equivalent product whenever the statutory conditions are met. On the MPJE, an answer implying substitution is the pharmacist's optional courtesy is wrong for New York; substitution is a default duty that only an unambiguous prohibition can turn off.

The Drug-Product Substitution Rule — § 6816-a(1)

A pharmacist shall substitute a less expensive drug product containing the same active ingredient(s), dosage form, and strength as the product prescribed, ordered, or demanded, when all of the following are true:

1. The prescription form permits it. Written prescriptions must comply with Education Law § 6810(6)'s form requirements — meaning the prescriber has not marked the prescription to prohibit substitution. For an oral prescription, the prescriber must expressly state, at the time it is called in, whether substitution is permitted or prohibited.
2. The substitute is on the state's approved list. The substituted product must appear on the approved drug products list maintained under Public Health Law § 206 — New York's equivalent of an "AB-rated" formulary. A pharmacist may not substitute an off-list product no matter how similar it appears to the prescribed drug.
3. Labeling duty. The pharmacist must indicate on the label affixed to the immediate container the name and strength of the drug product actually dispensed and its manufacturer, unless the prescriber specifically states otherwise.
4. Recordkeeping duty. The prescription record itself must document the brand name or the manufacturer's name of the drug product dispensed, so the dispensing history is traceable back to the actual product given to the patient — not just the product originally written.

The Interchangeable Biological Product Rule — § 6816-a(3)–(4)

New York extends the same mandatory-substitution logic to interchangeable biological products — biologics the FDA has formally designated as interchangeable with a specific reference product (or with each other). Under § 6816-a(3), a pharmacist shall substitute a less expensive interchangeable biological product for the one prescribed when:

Biologics carry one duty that drug-product substitution does not: prescriber notification. Under § 6816-a(4), within five business days of dispensing a substituted biological product, the dispensing pharmacist (or a designee) must communicate to the prescriber the specific product provided — name and manufacturer. This notice may go through an electronic records system the prescriber can access, a fax, or another electronic method; telephone communication is a fallback only when electronic means are not available. This added duty exists because interchangeable biologics, unlike small-molecule generics, are not always structurally identical to the reference product, so continuity-of-care tracking matters more.

Biosimilar vs. Interchangeable: Why the Distinction Drives § 6816-a

Not every biosimilar qualifies for pharmacy-level substitution under § 6816-a — only those the FDA has specifically designated interchangeable. Under the federal Biologics Price Competition and Innovation Act (BPCIA) framework, a biosimilar is a biologic shown to be highly similar to a reference product with no clinically meaningful differences in safety or effectiveness, but it still generally requires a new prescription to switch a patient onto it. An interchangeable biological product must clear a materially higher bar — including, where required, switching studies showing that alternating between the interchangeable product and its reference product does not increase safety or efficacy risk compared to using the reference product alone. Because only FDA-designated interchangeable products meet that higher bar, they are the only biologics § 6816-a authorizes a pharmacist to substitute at the counter without contacting the prescriber first; a merely "biosimilar" (but not interchangeable) product cannot be substituted under this statute even if it is clinically similar.

How the Prescriber Turns Off Substitution

A prescriber prohibits substitution by using the mechanism built into the prescription form under Education Law § 6810(6) (for written prescriptions) or by expressly stating "no substitution" at the time an oral prescription is called in. Silence on a properly formatted written prescription is not a prohibition — the statutory default is substitution.

Layered Discipline: § 29.7(a)(6)

As covered in § 9.1, 8 NYCRR § 29.7(a)(6) separately makes it unprofessional conduct to fail to write the manufacturer's (and distributor's, if different) name on both the prescription and the label when dispensing a generic or interchangeable biological product. This regulation and § 6816-a's labeling duty reinforce each other: the statute creates the substitution and labeling obligation, and the misconduct regulation is the Board's enforcement hook if a pharmacist skips it.

Common MPJE Traps

• Treating New York generic substitution as optional or discretionary — it is a default duty, not a courtesy, once the statutory conditions are met.
• Substituting a therapeutically similar but not Public Health Law § 206-listed product — off-list substitution is not authorized even when the active ingredient, dosage form, and strength all match.
• Forgetting the 5-business-day prescriber notification for biologic substitutions — this duty does not exist for ordinary small-molecule generic drug substitution.
• Assuming a phone call is always an acceptable way to notify the prescriber of a biologic substitution — it is the fallback method only when electronic communication is unavailable.